Inhibition of NEDD8-conjugation pathway by novel molecules: potential approaches to anticancer therapy

Mol Oncol. 2012 Jun;6(3):267-75. doi: 10.1016/j.molonc.2012.01.003. Epub 2012 Jan 21.

Abstract

Cancer cells can survive through the upregulation of cell cycle and the escape from apoptosis induced by numerous cellular stresses. In the normal cells, these biological cascades depend on scheduled proteolytic degradation of regulatory proteins via the ubiquitin-proteasome pathway. Therefore, interruption of regulated proteolytic pathways leads to abnormal cell-proliferation. Ubiquitin ligases called SCF complex (consisting of Skp-1, cullin, and F-box protein) or CRL (cullin-RING ubiquitin ligase) are predominant in a family of E3 ubiquitin ligases that control a final step in ubiquitination of diverse substrates. To a great extent, the ubiquitin ligase activity of the SCF complex requires the conjugation of NEDD8 to cullins, i.e. scaffold proteins. This review is anticipated to review the downregulation system of NEDD8 conjugation by several factors including a chemical compound such as MLN4924 and protein molecules (e.g. COP9 signalosome, inactive mutant of Ubc12, and NUB1/NUB1L). Since the downregulation of NEDD8 conjugation affects cell-cycle progression by inhibiting the ligase activity of SCF complexes, such knowledge in the NEDD8-conjugation pathway will contribute to the more magnificent therapies that selectively suppress tumorigenesis.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Cyclopentanes / pharmacology
  • Cyclopentanes / therapeutic use
  • Humans
  • NEDD8 Protein
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism*
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use
  • SKP Cullin F-Box Protein Ligases / metabolism
  • Signal Transduction / drug effects
  • Ubiquitins / metabolism*

Substances

  • Cyclopentanes
  • NEDD8 Protein
  • NEDD8 protein, human
  • Pyrimidines
  • Ubiquitins
  • SKP Cullin F-Box Protein Ligases
  • pevonedistat